JP2023512828A5 - - Google Patents
Info
- Publication number
- JP2023512828A5 JP2023512828A5 JP2022548125A JP2022548125A JP2023512828A5 JP 2023512828 A5 JP2023512828 A5 JP 2023512828A5 JP 2022548125 A JP2022548125 A JP 2022548125A JP 2022548125 A JP2022548125 A JP 2022548125A JP 2023512828 A5 JP2023512828 A5 JP 2023512828A5
- Authority
- JP
- Japan
- Prior art keywords
- formula
- pharmaceutical composition
- pharmaceutically acceptable
- composition according
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062971752P | 2020-02-07 | 2020-02-07 | |
| US62/971,752 | 2020-02-07 | ||
| US202063120604P | 2020-12-02 | 2020-12-02 | |
| US63/120,604 | 2020-12-02 | ||
| US202163134042P | 2021-01-05 | 2021-01-05 | |
| US63/134,042 | 2021-01-05 | ||
| PCT/US2021/016920 WO2021158992A1 (en) | 2020-02-07 | 2021-02-05 | Improved methods and compositions for cromakalim prodrug therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023512828A JP2023512828A (ja) | 2023-03-29 |
| JP2023512828A5 true JP2023512828A5 (enExample) | 2024-02-14 |
Family
ID=77199473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548125A Pending JP2023512828A (ja) | 2020-02-07 | 2021-02-05 | クロマカリムプロドラッグ療法のための改善された方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220387457A1 (enExample) |
| EP (1) | EP4100003A4 (enExample) |
| JP (1) | JP2023512828A (enExample) |
| CN (1) | CN115768419A (enExample) |
| AU (1) | AU2021215932A1 (enExample) |
| CA (1) | CA3166579A1 (enExample) |
| WO (1) | WO2021158992A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10981951B2 (en) * | 2014-01-31 | 2021-04-20 | Mayo Foundation For Medical Education And Research | Therapeutics for the treatment of glaucoma |
| CA3159771A1 (en) | 2019-12-12 | 2021-06-17 | Thurein M. Htoo | Controlled-delivery cromakalim prodrugs |
| EP4384162A4 (en) * | 2021-08-12 | 2025-06-04 | Qlaris Bio, Inc. | Compositions and methods for extended-release bromo-kallim therapy |
| CN115058440B (zh) * | 2022-06-08 | 2023-08-15 | 郑州轻工业大学 | 催化合成天然蔗糖酯的工程菌及其构建方法和应用 |
| GB202211936D0 (en) * | 2022-08-16 | 2022-09-28 | Royal Veterinary College | Method and treatment for diabetes |
| IL320428A (en) * | 2022-11-04 | 2025-06-01 | Qlaris Bio Inc | Topical ophthalmic administration of cromolyns |
| CN119548509B (zh) * | 2024-11-21 | 2025-11-14 | 中山大学中山眼科中心 | 一种小分子化合物组合物及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308062D0 (en) * | 1983-03-24 | 1983-05-05 | Beecham Group Plc | Active compounds |
| WO1989010757A1 (en) * | 1988-05-10 | 1989-11-16 | Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis | New ophthalmic preparation for treating glaucoma |
| US5565560A (en) * | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
| CN101327325A (zh) * | 2002-07-30 | 2008-12-24 | 奥默罗斯公司 | 眼科冲洗液及方法 |
| DK2838533T3 (da) * | 2012-04-16 | 2017-11-27 | Univ Case Western Reserve | Sammensætninger og fremgangsmåder til at modulere 15-pgdh-aktivitet |
| US10981951B2 (en) * | 2014-01-31 | 2021-04-20 | Mayo Foundation For Medical Education And Research | Therapeutics for the treatment of glaucoma |
| MA41252A (fr) * | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
| WO2018047175A1 (en) * | 2016-09-08 | 2018-03-15 | Regenera Pharma Ltd. | Compositions comprising triterpenoids and uses thereof for treating optic neuropathy |
| CA3159771A1 (en) * | 2019-12-12 | 2021-06-17 | Thurein M. Htoo | Controlled-delivery cromakalim prodrugs |
-
2021
- 2021-02-05 AU AU2021215932A patent/AU2021215932A1/en not_active Abandoned
- 2021-02-05 CA CA3166579A patent/CA3166579A1/en active Pending
- 2021-02-05 CN CN202180024624.5A patent/CN115768419A/zh active Pending
- 2021-02-05 JP JP2022548125A patent/JP2023512828A/ja active Pending
- 2021-02-05 EP EP21750576.7A patent/EP4100003A4/en active Pending
- 2021-02-05 WO PCT/US2021/016920 patent/WO2021158992A1/en not_active Ceased
-
2022
- 2022-08-05 US US17/882,270 patent/US20220387457A1/en not_active Abandoned